BioSpace News Archive

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies to address unmet medical needs, recently highlighted to members of the investment community its clinical and operational progress through a series of webinars hosted by FORCE Wealth with presentations by Brian M. Culley, Chief Executive Officer.

EuBiologics (KOSDAQ: 206650), a South Korean biotech company, announced on Jan 21st that EuCorVac-19, a COVID-19 vaccine candidate developed by EuBiologics, was approved to conduct Phase I/II clinical trials by the Ministry of Food and Drug Safety, immediately entering into the Phase I trial.

COVAXX, a subsidiary of United Biomedical, Inc. (UBI), has announced receipt of FDA Emergency Use Authorization (EUA) for its COVID-19 antibody test, UBI SARS-CoV-2 ELISA

Pascal Biosciences, Inc. (TSXV:PAS)(OTC PINK:BIMUF), will present at the first Cannabinoid Derived Pharmaceuticals Industry Review Summit today. Dr. Patrick Gray, CEO of Pascal Biosciences, will present advancements of Pascals development program for treatment of glioblastoma with PAS-403.

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”), today announced that LUMIFY ® (brimonidine tartrate ophthalmic solution 0.025%) redness reliever eye drops have received approval from the Ministry of Food and Drug Safety (MFDS) in South Korea .

Revolutionary Virtual Care and Prescription Drug Management System Designed to Support Patients and Providers in Digital Health Platform

CASI Pharmaceuticals, Inc. today announces that it will host a Key Opinion Leader call on BI-1206 for relapsed or refractory Non-Hodgkin’s Lymphoma on Thursday, January 28, 2021 at 11:30 a.m. Eastern Time (5:30 p.m. CET).

IMBiotechnologies Ltd. (“IMB” or the “Company”) today announced that it has signed an agreement with Canadian Hospital Specialties (“CHS”) for the exclusive right to distribute Ekobi® Embolization Microspheres (“Ekobi”) in Canada. “CHS has expertise in the distribution of a broad range of medical d

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced the completion of enrollment for its explanatory study

Pharma Industry Veteran in Vaccines will Assume Role Full Time March 2, 2021, with Focus on Developing Product Pipeline in Infectious Diseases